SUMBUL ISLAM: Open Payments
NPI 1992898860 · SHERMAN, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$667 in 44 payments from 13 companies in 2025. Trend: 2023 $724 · 2024 $938 · 2025 $667
Food & beverage: $667
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 11 | $149 |
| Novo Nordisk Inc | 6 | $106 |
| GlaxoSmithKline, LLC. | 5 | $96 |
| PFIZER INC. | 3 | $56 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $51 |
| Phathom Pharmaceuticals, Inc. | 7 | $48 |
| Amgen Inc. | 2 | $36 |
| AstraZeneca Pharmaceuticals LP | 2 | $29 |
| Corcept Therapeutics | 1 | $24 |
| Abbott Laboratories | 1 | $24 |
Products named: VRAYLAR, TRELEGY ELLIPTA, Ozempic, CAPLYTA, VOQUEZNA, AIRSUPRA, LINZESS, ELIQUIS.
Industry payments across TX — which companies pay providers there.
